Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate‐risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006‐intermediate‐risk trial
暂无分享,去创建一个
M. Bernard | G. Guillerm | C. Récher | J. Hamel | N. Ifrah | P. Cornillet‐Lefèbvre | J. Delaunay | N. Vey | I. Luquet | C. Humbrecht | D. Bouscary | O. Blanchet | M. Hunault-Berger | E. Delabesse | E. Jourdan | E. Gyan | A. Pigneux | D. Caillot | J. Marolleau | A. Banos | Y. Hicheri | P. Dumas | P. Turlure | C. Bulabois | P. Peterlin | M. Ojeda-Uribe | A. Bouvier | Marie-Pierre Ledoux | É. Daguindau | E. Tavernier | C. Himberlin | C. Simand | H. Zerazhi | M. Carré | M. P. G. Hernanz | V. Dorvaux | R. Guièze | A. Magda | Gabrielle Roth Guepin | Marie Christine Béné | É. Delabesse
[1] M. Konopleva,et al. Prognostic significance of baseline FLT3‐ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib , 2019, American journal of hematology.
[2] E. Estey,et al. Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Kanda,et al. Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. , 2018, Blood advances.
[4] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[5] C. Eberlein,et al. Differences Between CEBPA bZIP and TAD Mutations and Their Effect on Outcome-an Analysis in 4578 Patients with Acute Myeloid Leukemia , 2016 .
[6] W. Hiddemann,et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. , 2016, Blood.
[7] Nicola D. Roberts,et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.
[8] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[9] D. Grimwade,et al. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. , 2016, Blood.
[10] K. Döhner,et al. Intermediate-risk acute myeloid leukemia therapy: current and future. , 2014, Hematology. American Society of Hematology. Education Program.
[11] E. Estey,et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. , 2014, The Lancet. Oncology.
[12] R. Hills,et al. Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. , 2014, Blood.
[13] C Haferlach,et al. The role of different genetic subtypes of CEBPA mutated AML , 2014, Leukemia.
[14] R. Larson,et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. , 2013, Blood.
[15] Benjamin J. Raphael,et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.
[16] H. Dombret,et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study , 2012, The Lancet.
[17] N. Socci,et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.
[18] L. Créancier,et al. Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience , 2011, Oncotarget.
[19] Erdogan Taskesen,et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. , 2011, Blood.
[20] A. Tefferi,et al. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms , 2010, Leukemia.
[21] R. Hills,et al. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] L. Shaffer,et al. Nomenclature Evolution: Changes in the ISCN from the 2005 to the 2009 Edition , 2010, Cytogenetic and Genome Research.
[23] Bob Löwenberg,et al. Review Articles (434 articles) , 2008 .
[24] Daniel Birnbaum,et al. Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia , 2009, British journal of haematology.
[25] Axel Benner,et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.
[26] Adam J Mead,et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. , 2008, Blood.
[27] J. Cayuela,et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. , 2005, Blood.
[28] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] N. Harris,et al. The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.
[30] Pu Zhang,et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia , 2001, Nature Genetics.
[31] H. Kaneko,et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.
[32] Richard O. Duda,et al. Pattern classification and scene analysis , 1974, A Wiley-Interscience publication.
[33] Zhong Li-ye,et al. Early Allogeneic Stem-Cell Transplantation for Young Adults with Acute Myeloblastic Leukemia in First Complete Remission: An Intent-to-Treat Long-Term Analysis of the BGMT Experience , 2007 .